New 1,4-Dihydropyridines Endowed with NO-Donor and Calcium Channel Agonist Properties

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2688-2693

  Visentin, Sonja ^a   Rolando, Barbara ^a   Di Stilo, Antonella ^a   Fruttero, Roberta ^a   Novara, Monica ^a   Carbone, Emilio ^a   Roussel, Christian ^b   Vanthuyne, Nicolas ^b   Gasco, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL STIMULATING AGENT; CYANOFUROXAN; FURAZAN DERIVATIVE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA; ARTICLE; CALCIUM TRANSPORT; CHIRAL CHROMATOGRAPHY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; ENANTIOMER; HEART PAPILLARY MUSCLE; INOTROPISM; MALE; NONHUMAN; RACEMIC MIXTURE; RAT; STRUCTURE ANALYSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AORTA, THORACIC; CALCIUM CHANNELS, L-TYPE; CELL LINE, TUMOR; DIHYDROPYRIDINES; MALE; MUSCLE, SMOOTH; NITRIC OXIDE DONORS; PAPILLARY MUSCLES; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; STEREOISOMERISM; VASODILATOR AGENTS;

EID: 2342559211     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031109v     Document Type: Article

References (18)

1. 2+ Channels Ligands: Structure-Function Relationships of the 1,4-Dihydropyridines. Med. Res. Rev. 1989, 9, 123-180.
2. Goldmann, S.; Stoltefuss, J. 1,4-Dihydropyridines: Effects of Chirality and Conformation on the Calcium Antagonist and Calcium Agonist Activities. Angew. Chem., Int. Ed. Engl. 1991, 30, 1559-1578.
3. 2+-channels. J. Pharmacol. Exp. Ther. 1988, 244, 699-708.
4. Goldenberg, I. F.; Cohn, J. N. New Inotropic Drugs for Heart Failure. J. Am. Med. Assoc. 1987, 258, 493-496.
5. Erhardt, P. W. In Search for the Digitalis Replacement. J. Med. Chem. 1987, 30, 321-237.
6. Harabie, J. A.; Keefer, L. K. Nitric Oxide Donors. In Patophysiology and Clinical Applications of Nitric Oxide; Rubany, G. M., Ed.; Harwood Academic Publishers: Australia, 1999; pp 455-470.
7. Shan, R.; Howlett, S. E.; Knaus, E. E. Syntheses, Calcium Channels Agonist-Antagonist Modulation Activities, Nitric Oxide Release, and Voltage-Clamp Studies of 2-Nitrooxyethyl 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl) pyridine-5-carboxylate Enantiomers. J. Med. Chem. 2002, 45, 955-961.
8. Vo, D.; Nguyen, J.-T.; McEwen, C.-A.; Shan, R.; Knaus, E. E. Syntheses, Calcium Channels Agonist-Antagonist Modulation Effects, and Nitric Oxide Release Studies of [3-(Benzensulfonyl)furoxan-4-yloxyl alkyl 1,4-Dihydro-2,6-dimethyl-5-nitro-4-(2-trifluoromethyphenyl, benzofurazan-4-yl, 2-,3-, or 4-pyridyl)-3-pyridinecarboxylates. Drug Dev. Res. 2002, 56, 1-16.
9. Di Stilo, A.; Visentin, S.; Cena, C.; Gasco, A. M.; Ermondi, G.; Gasco, A. New 1,4-Dihydropyridines Conjugated to Furoxanyl Moieties, Endowed with Both Nitric Oxide-like and Calcium Channel Antagonist Vasodilator Activities. J. Med. Chem. 1998, 41, 5393-5401.
10. Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli, U.; Gasco, A. Water Soluble Furoxan Derivatives as NO-Prodrugs. J. Med. Chem. 1997, 40, 2288, 463-469.
11. 2+ channels in rat insulinoma and human pancreatic β-cells. Pflügers Archiv. 1998, 423, 462-471.
12. 2+ channels in rat insulinoma RINm5F cells by ω-conotoxin MVIIC. Pflügers Archiv. 1995, 429, 762-771.
13. Sarkar, D.; Vallance, P.; Harding, S. E. Nitric Oxide: not just a negative inotrope. Eur. J. Heart Failure 2001, 3, 527-534.
14. Kerwin, J. F., Jr.; Lancaster, J. R., Jr.; Feldman, P. L. Nitric Oxide: A New Paradigm for Second Messengers. J. Med. Chem. 1995, 38, 4343-4362.
15. 2+ channel modulation in bovine chromaffin cells. Neuron 1998, 20 (6), 1255-1268.
16. 2+-Channel Activator" BAY K 8644. Pharmacol. Toxicol. 1988, 63, 20-25.
17. Kwon, Y. W.; Franckowiak, G.; Langes, D. A.; Hawthorn, M.; Joslyn, A.; Triggle, D. J. Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activators related to Bay K 8644 in smoth muscle, cardiac muscle and neuronel preparations. Naunyn-Shmiedeberg's Arch Pharmacol 1989, 339, 19-30.
18. Wakabayashi, I.; Sakamoto, K.; Kakishita, E.; Potentialing Effect of Daunorubicin on vasocontractile response to KCl and BAY K 8644 in rat aorta. J. Pharm. Pharmacol. 1990, 42, 716-719.